News & Events


20 October 2023

19 October 2023, Sydney, Australia.


Published in Nature Portfolio’s npj Digital Medicine, SNAC’s clinically integrated AI-based tool, iQ-SolutionsTM, outperformed standard radiology reports for detection of disease activity in a multicentre, real-world multiple sclerosis (MS) cohort.


In the largest and most comprehensive clinical validation of a quantitative MRI monitoring tool for MS, the sensitivity of SNAC’s iQ-SolutionsTM for the detection of active disease (the development of new or enlarging lesions) was 93.3%, compared to only 58.3% for standard radiology reports, in 397 multi-centre MRI scan pairs acquired in routine practice.


“Targeting both clinical and radiological quiescence is known to reduce long term disability in MS. Our study confirms the importance of artificial intelligence support for radiologists to improve patient outcomes”, said the study’s lead author, Dr Michael Barnett, Professor of Neurology at the University of Sydney and senior neurologist at Royal Prince Alfred Hospital, Sydney.


The fully-automatic tool also matched widely accepted gold standards for measuring accelerated loss of brain tissue between scans collected at clinically relevant intervals, whereas even more severe brain atrophy (>0.8% loss over 1 year) was not appreciated in radiology reports.


Dr Tim Wang, SNAC’s Chief Operating Officer and senior author, said “iQ-SolutionsTM is seamlessly integrated with the usual radiology workflow, representing a “zero-click” solutions for radiologists. Improving both accuracy and productivity, we see iQ-SolutionsTM as a value-add for radiologists, who need to review many hundreds of images per MRI scan to detect only 1-2 small changes that might lead to a change in the patient’s treatment”


About SNAC

Established in 2012, Sydney Neuroimaging Analysis Centre (SNAC) is a medical imaging analysis and research SME that integrates clinical imaging and neurosciences with engineering research. SNAC uses advanced technologies such as artificial intelligence, cloud computing, and big data analytics to develop cutting-edge, clinically-informed imaging biomarkers of disease progression and therapeutic efficacy; and the software tools and products to implement these both research and clinical environments.  SNAC is also the sole regulatory-compliant (ISO-9001, ISO-13485 certified, CFR-21 Part 11 compliant) provider of central neuro-MRI reading for pharma Phase II-IV clinical trials in the Southern hemisphere.


See Article, blog or contact for more information